Radiation oncologist; Artera clinical development team
Charlottesville, VA
Joined May 2018
- Tweets344
- Following744
- Followers1.2K
- Likes1.8K
Tim Showalter retweeted
In this episode we chat w @othman CEO/cofounder @Color - give us a listen for a story of impact and inspiration for how health technology can improve care delivery podcasts.apple.com/us/podcas…
Tim Showalter retweeted
We’re proud to have @Benioff on Artera’s board, helping shape how AI transforms precision medicine.
Check out his latest interview on the future of AI in business via @ChiefExecGrp: heyor.ca/mpLN8u
#AIinHealthcare #MarcBenioff #Leadership
Tim Showalter retweeted
Congratulations to our friends and colleagues @arteraAI —their multimodal #ArtificialInteligence platform is revolutionary and applicable clinically. Bravo @arteraAI team! @TIME
time.com/7094698/arterai-mul…
Tim Showalter retweeted
Dr. @TimShowalter1 from @arteraAI presented the data from prostate cancer and discussed possibilities of integrating tissue AI analysis in RCC. Very promising to have AI integration in RCC. #KCRS23 @OncoAlert
Tim Showalter retweeted
Can we take lessons learned from #prostatecancer into #kidneycancer?
@TimShowalter1 says yes!
@kidneycan @kidneycancer @kcCURE #KCRS23
Tim Showalter retweeted
Are you passionate about #artificialintelligence and innovation in medical care? Join our team!
Are you looking to make a difference with your career? #ArteraAI is seeking a #ClinicalResearch Associate.
➡️ Get full job details and apply here today: bit.ly/3PhrDVr
ALT An ArteraAI Careers graphic promoting the Clinical Reseach Associate position.
Tim Showalter retweeted
Shark tank at ABS#2023 presentation on Chat GPT for brachy education @TimShowalter1 @PranshuMohindra
Tim Showalter retweeted
Did you catch Tim Showalter's presentation at #BiomarkersSeries23? 🇬🇧
Members of the Artera team met with attendees to discuss how the #ArteraAI #ProstateTest can help identify patients who will benefit from therapy intensification.
➡️ Learn more: artera.ai/our-test/
Tim Showalter retweeted
What if there was a way to identify the patients who would benefit from therapy intensification?
With #ArteraAI, there is. 💙
➡️ Learn more about The ArteraAI #ProstateTest: artera.ai/our-test
Tim Showalter retweeted
The Artera team is heading to #BiomarkersSeries23 2/27-2/28 in Manchester. 🇬🇧
Don't miss Dr. Tim Showalter's presentation "Pathology-Based Deep Learning Tools to Personalize Treatment Decisions: #ArteraAI #ProstateTest Development & Validation" on 2/27! bit.ly/3XEatCb
Tim Showalter retweeted
🏎️ FORMULA 509 @DrPaulNguyen #GU23 #pcsm @OncoAlert
Salvage RT (med dose 68.4 Gy, 26% nodes tx) w 6 mos ADT ±intensification w AAP/Apa
Overall PFS HR 0.71 p=.06
However pre-specified subgrp PSA>0.5 PFS HR 0.5, P=.03; MFS HR 0.32 p=.02 👉 potential alt to longer ADT in this pop
Tim Showalter retweeted
#ArteraAI is at #GU23!
Don't miss today's presentation with @DrSpratticus, as he shares results from six phase III randomized trials and how the use of MMAI prognostic biomarkers may improve the ability to assess risk in patients with #prostatecancer.⚕️ #ASCOGU
Tim Showalter retweeted
Thrilled to see a great turnout for the amazing IBC update from the incomparable @FilipaLynce @IBC_DanaFarber highlighting progress in biology, partnership with @SusanGKomen @MDAndersonNews for diagnosis tools and efforts to move good M1 tx to the M0 IBC setting! #SABCS2022
Tim Showalter retweeted
More science highlights from ASTRO on UroToday! #ASTRO22 #ASTRO2022 #AI #ArteraAI
urotoday.com/conference-high… via @urotoday
Tim Showalter retweeted
Our science was highlighted on UroToday! #ASTRO22 #ASTRO2022 #AI #ArteraAI
urotoday.com/conference-high… via @urotoday
Tim Showalter retweeted
Fantastic work and beautifully presented @SouMyajiT_RO
#ASTRO22 continues! Great presentation by @SouMyajiT_RO on the impact of patient reported QOL on prostate cancer survivorship.
➡️Treatment induced improvement in global QOL is a predictor for improved disease-free and overall survivorship in localized prostate cancer.
Tim Showalter retweeted
Join us at the plenary session to see Dr. Jonathan Tward present "Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology" at 1:46 PM, Stars at Night Ballroom! #ASTRO22 #ASTRO2022 #AI #ArteraAI
Tim Showalter retweeted
Great discussion on Artera's prognostic risk stratification tool by Dr. Amar Kishan! @AmarUKishan #ASTRO22 #ASTRO2022 #AI #ArteraAI
Tim Showalter retweeted
All things prostate…we come from different parts of the world, practice in different ecosystems, but the same goal…this was fun and educational. #Astro22 – at San Antonio, TX
Tim Showalter retweeted
Intriguing data - Multimodal AI deep learning of histopathology of NRG/RTOG trials. ~5,500 patients with #prostatecancer. 83% of NCCN intermediate risk would be reclassified to MMAI low, with <10% risk of distant Mets #pcsm @ASTRO_org #astro22 @OncoAlert
